Are you still long on LPCN?
I Am Long.
How long have you been in LPCN?
I Came Across Lipocine in August of last year.
Do you care to share your average pps or number of shares?
I have bought and sold my holdings several times to place other trades, ultimately resulting in an increase in current shares held.
It appears that Lipocine has not interest in suing in court. What's the court status?
Court status is apparent, awaiting trial scheduling. Lipocine brought the suit against Clarus to sue in court.
I don't think Lipocine is going to get a favorable deal for marketing Tlando. Am I being too negative? When will we hear about a partnership?
It is my opinion the litigation against Clarus and/or Phase 2 1144 results would need to wrap up before a partnering announcement. However, talks are obviously ongoing per an overly excited birdy named Patel. TLando is a money maker, any partner will know that!
It is anybodys guess as to when a good catalyst will hit; analyst upgrade, pipeline news, partnership, trial, nash results, etc.. so my mention of selling to run trades is risky. But, I've been lucky with timing and I Only jump ship on damn good prospects of a daytrade or overnight hold. Long and short alike. You might try paper trading your position (no risk) to see how you do with that, then jump in sometime if you feel confident. No risk, no reward!
As for Long term vs under 12 month holds, taxes are not my concern. Profit is, and if I turn a buck into two and have to pay forty cents, I'm still sixty cents up!
G'luk
Recent LPCN News
- Form 8-K - Current report • Edgar (US Regulatory) • 05/26/2026 09:08:04 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/19/2026 01:00:16 PM
- Lipocine Announces LPCN 1154 Phase 3 Data Accepted for Oral Presentation at 2026 ASCP Annual Meeting • PR Newswire (US) • 05/19/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/18/2026 01:00:24 PM
- Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors • Edgar (US Regulatory) • 05/15/2026 09:00:59 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/07/2026 08:09:00 PM
- Lipocine Announces Financial Results for the First Quarter Ended March 31, 2026 • PR Newswire (US) • 05/07/2026 08:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/07/2026 01:05:14 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/07/2026 01:00:59 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/21/2026 09:12:48 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/21/2026 09:01:02 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/21/2026 08:05:27 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/07/2026 10:27:25 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/06/2026 11:01:22 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/06/2026 10:33:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 09:05:58 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/02/2026 01:40:13 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/02/2026 01:35:13 PM
- Lipocine Reports Topline Safety and Efficacy Results for LPCN 1154 in Patients with Postpartum Depression • PR Newswire (US) • 04/02/2026 12:00:00 PM
- Lipocine Announces Financial Results for the Full Year Ended December 31, 2025 • PR Newswire (US) • 03/10/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/10/2026 10:13:03 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/04/2026 09:05:52 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 02/26/2026 10:33:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/18/2026 02:37:58 PM
